The Technical AnalystExchange: STO Sector: Healthcare Industry: Diagnostics & Research
Vimian Group AB (publ) Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.61% SEK35.90
America/New_York / 17 mai 2024 @ 11:29
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 18 293 mill |
| EPS: | 0.230 |
| P/E: | 156.09 |
| Earnings Date: | Aug 14, 2024 |
| SharesOutstanding: | 509.54 mill |
| Avg Daily Volume: | 0.478 mill |
| RATING 2024-05-17 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 7.90x |
| Company: PE 156.09 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 3.23x |
| Company: PE 156.09 | industry: PE 48.39 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
SEK-11.74 (-132.71%) SEK-47.64 |
| Date: 2024-05-18 |
| Expected Trading Range (DAY) |
|---|
|
SEK 34.35 - 37.45 ( +/- 4.31%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | SEK35.90 (3.61% ) |
| Volume | 0.831 mill |
| Avg. Vol. | 0.478 mill |
| % of Avg. Vol | 173.75 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VIMIAN.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
VIMIAN.ST
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. The company was incorporated in 2020 and is headquartered in Stockholm, Sweden.